Literature DB >> 1516411

Proliferative characteristics of fibroblast lines derived from open lung biopsy specimens of patients with IPF (UIP).

T Mio1, S Nagai, M Kitaichi, A Kawatani, T Izumi.   

Abstract

We compared the doubling time of fibroblasts derived from idiopathic pulmonary fibrosis (usual interstitial pneumonia) (IPF [UIP]) lung tissues and control fibroblasts, cultured in usual growth medium, and examined the response of these fibroblasts to platelet-derived growth factor (PDGF) and prostaglandin E2 (PGE2). Ten fibroblast lines from open lung biopsy specimens of patients with IPF (UIP) and ten control fibroblast lines from surgically resected lung tissue of patients with limited lung diseases were established. The average doubling time of fibroblast lines was 32.0 +/- 6.0 h (mean +/- SD) in UIP and 33.2 +/- 10.4 h in controls, showing no difference between the two groups. To examine the responses of fibroblasts to PDGF and PGE2 and the differences between fibroblasts derived from fibrotic tissues with different intensity of fibrosis, lung specimens from five patients with IPF were subdivided into two groups, higher-intensity fibrotic lesions (H) and lower-intensity fibrotic lesions (L). The fibroblast lines were established separately. 3H-thymidine uptake with or without PDGF or PGE2 was examined. Results were expressed as the index of thymidine incorporation into the fibroblasts. There were no differences in the doubling times and the responses to PDGF and PGE2 between H and L. There were no differences between control and H regarding their response to PDGF. In response to PGE2, the growth inhibition for H was significantly decreased compared with the control (p less than 0.05). There was no difference in growth inhibition between H and L. The finding that PGE2 inhibits fibroblast proliferation less in UIP lung tissue suggests that fibroblasts from UIP were functionally altered cells or, to some extent, out of normal regulation. These results suggest an abnormal proliferation of fibroblasts observed in IPF (UIP).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516411     DOI: 10.1378/chest.102.3.832

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

Review 1.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

Review 2.  Epithelial-mesenchymal interactions in pulmonary fibrosis.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Semin Respir Crit Care Med       Date:  2006-12       Impact factor: 3.119

3.  Decreased prostaglandin E2 synthesis by lung fibroblasts isolated from rats with bleomycin-induced lung fibrosis.

Authors:  F Ogushi; T Endo; K Tani; K Asada; T Kawano; H Tada; K Maniwa; S Sone
Journal:  Int J Exp Pathol       Date:  1999-02       Impact factor: 1.925

4.  Regulation and Relevance of Myofibroblast Responses in Idiopathic Pulmonary Fibrosis.

Authors:  Meagan W Moore; Erica L Herzog
Journal:  Curr Pathobiol Rep       Date:  2013-09

5.  Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity.

Authors:  Eric S White; Rachelle G Atrasz; Emily G Dickie; David M Aronoff; Vuk Stambolic; Tak W Mak; Bethany B Moore; Marc Peters-Golden
Journal:  Am J Respir Cell Mol Biol       Date:  2004-11-11       Impact factor: 6.914

6.  UM-Chor1: establishment and characterization of the first validated clival chordoma cell line.

Authors:  John Henry Owen; Christine M Komarck; Anthony C Wang; Waleed M Abuzeid; Richard F Keep; Erin L McKean; Stephen Sullivan; Xing Fan; Mark E P Prince
Journal:  J Neurosurg       Date:  2017-04-21       Impact factor: 5.115

7.  Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts.

Authors:  Aleksandar Marinković; Fei Liu; Daniel J Tschumperlin
Journal:  Am J Respir Cell Mol Biol       Date:  2013-04       Impact factor: 6.914

8.  Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia.

Authors:  Steven K Huang; Scott H Wettlaufer; Cory M Hogaboam; Kevin R Flaherty; Fernando J Martinez; Jeffrey L Myers; Thomas V Colby; William D Travis; Galen B Toews; Marc Peters-Golden
Journal:  Am J Respir Crit Care Med       Date:  2007-10-04       Impact factor: 21.405

9.  "Scar-cinoma": viewing the fibrotic lung mesenchymal cell in the context of cancer biology.

Authors:  Jeffrey C Horowitz; John J Osterholzer; Antonia Marazioti; Georgios T Stathopoulos
Journal:  Eur Respir J       Date:  2016-03-30       Impact factor: 16.671

10.  Enhanced migration of fibroblasts derived from lungs with fibrotic lesions.

Authors:  H Suganuma; A Sato; R Tamura; K Chida
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.